UBA1 and acute myeloid leukemia: We confirmed UBA1 specificity, as mutated cells did not exhibit differential sensitivity to other commonly used drugs to treat MDS and AML, cytarabine, daunorubicin, pladienolide B, and venetoclax, compared to SF3B1WT cells (supplementary Fig. 6A–D).